Dr. Arthur P. Bollon is the Co-Founder, President, and CEO of HemoBioTech, Inc. He’s a scientist, executive, and entrepreneur, with over 25 years experience in biotechnology. Co-Founder of HemoBioTech, developing potentially the first viable substitute for human blood. Also co-Founded Biogress (a biotech service company) and Cytoclonal Pharmaceutics, raising some $65 million, then implementing a licensing agreement with Bristol-Myers Squibb and acquiring Nobel Prize technology for computer based drug design.
The author of more than 50 scientific communications. Also served as Editor of the CRC Press Publication “Recombinant DNA Products: Insulin, Interferon and Growth Hormone.” At one time Director of Genetic Engineering at Wadley Cancer Center and Assistant Professor, University of Texas Southwestern Medical School, Dallas.